alexa
Reach Us +441414719275
Duration of Isoniazid Prophylaxis in HIV-Infected Individuals Living In Endemic Areas of Tuberculosis | OMICS International
ISSN 2155-6113
Journal of AIDS & Clinical Research

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business
All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Duration of Isoniazid Prophylaxis in HIV-Infected Individuals Living In Endemic Areas of Tuberculosis

Roberto A Accinelli*

Instituto de Investigaciones de la Altura Universidad Peruana Cayetano Heredia Lima, Lima, Peru

*Corresponding Author:
Roberto A Accinelli
Instituto de Investigaciones
de la Altura Universidad Peruana
Cayetano Heredia Lima, Lima, Peru
Tel: 51- 998119480
E-mail: [email protected]

Received date: March 27, 2015; Accepted date: May 04, 2015; Published date: May 12, 2015

Citation: Accinelli RA (2015) Duration of Isoniazid Prophylaxis in HIV-Infected Individuals Living In Endemic Areas of Tuberculosis. J AIDS Clin Res 6:456. doi:10.4172/2155-6113.1000456

Copyright: © 2015 Accinelli RA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of AIDS & Clinical Research

Patients with HIV infection represent a substantial fraction of the total population of patients with active tuberculosis infection. In 2008, approximately 709,000 (7.7%) of new tuberculosis disease cases and 200,000 tuberculosis-related deaths were estimated to have occurred in HIV positive individuals. In the developing world, tuberculosis has emerged as the most common opportunistic infection and the leading cause of death in HIV infected patients [1]. In regions where tuberculosis is prevalent, 44% of HIV patients could develop tuberculosis in the absence of preventive therapy or HAART [2].

Currently available strategies to prevent tuberculosis are effective. In 10 trials of tuberculosis prevention including a total of 5762 patients with HIV infection, preventive therapy was associated with a 32% overall reduction in the risk of developing active tuberculosis. In the four trials examining the efficacy of isoniazid therapy for HIV infected individuals with a positive tuberculin skin test, the rates of prevention were even better, 62% [3]. These impressive results have generated broad consensus supporting effective treatment of latent tuberculosis in HIV infected patients. In the current ATS/CDC guidelines, the authors recommend that all patients with HIV infection diagnosed with latent TB should receive treatment, and, when isoniazid is chosen, the duration of treatment should be extended to nine months rather than six [4].

However, accumulating evidence suggests these recommendations may not be sufficient. In a study of isoniazid administered to HIV positive patients with a positive or anergic tuberculin skin test in Uganda, Johnson et al. found that the protection conferred by isoniazid was lost a year after therapy. Similar findings were reported by Quigley et al. who found that, compared with the protection observed during isoniazid therapy, the protection was lower in the 1.5 to 2.5 years after completion of therapy and was absent after 2.5 years [5]. Samandari et al. reported that a 36 month course of isoniazid prophylaxis reduced the incidence of tuberculosis by 43% compared with a 6 month course [6]. Recently, Churchyard et al. showed that mass screening and treatment for latent tuberculosis in continuously exposed workers in South African gold mines reduced the rates of active tuberculosis by 58% while the workers were taking isoniazid but these effects were lost after therapy was stopped [7]. And Rangaka et al. found that the effect of isoniazid in HIV people treated for 12 months was greatest when they are still on treatment (HRu=0.52), than between 12–23 months (HRu=0.61) and for 24 or more months (HRu=0.78), but without statistical signification [8].

With these results we proposed to give permanently INH for HIV people living in an TB endemic area, as Peru, as primary prophylaxis when CD4 counts less than 200 cells/ml or if there is a history of oropharyngeal candidiasis and as secondary prophylaxis for HIV patients with previous TB disease for lifelong, unless reconstitution of the immune system occurs, similar to the recommendation in use in all the world for prevention of Pneumocystis [9].

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 12312
  • [From(publication date):
    May-2015 - Sep 24, 2019]
  • Breakdown by view type
  • HTML page views : 8500
  • PDF downloads : 3812
Top